What should be done for a patient with anti-Jka history, type O positive, and negative screen?

What should be done for a patient with anti-Jka history, type O positive, and negative screen?

• A. Crossmatch using units negative for Jka antigen
• B. Crossmatch random units since antibody is not demonstrating
• C. Request a new sample
• D. Repeat the screen with enzyme-treated cells

Answer: (A)

For a patient with a history of anti-Jka antibodies, it is essential to perform a crossmatch using units that are negative for the Jka antigen. This is because the presence of anti-Jka indicates that the patient's immune system has created antibodies against this specific antigen, which means that any compatible blood transfusion must not contain the Jka antigen. Using blood products that are Jka antigen negative helps prevent an adverse transfusion reaction, as introducing an incompatible antigen to the recipient could lead to hemolysis of the transfused red blood cells, which poses significant risks including febrile reactions, hemolytic anemia, or more severe complications. While crossmatching random units may seem viable due to the negative antibody screen, the history of anti-Jka presents a risk that should be mitigated by ensuring that the blood provided does not have the Jka antigen. Additionally, repeating the screen or requesting a new sample may not address the existing sensitization to the Jka antigen, as these actions do not change the compatibility requirements for the transfusion. Using enzyme-treated cells to repeat the screen also does not align with the best practice for managing known antibody history in transfusion settings. Thus, the safest and most effective practice is to utilize Jka

For a patient with a history of anti-Jka antibodies, it is essential to perform a crossmatch using units that are negative for the Jka antigen. This is because the presence of anti-Jka indicates that the patient's immune system has created antibodies against this specific antigen, which means that any compatible blood transfusion must not contain the Jka antigen.

Using blood products that are Jka antigen negative helps prevent an adverse transfusion reaction, as introducing an incompatible antigen to the recipient could lead to hemolysis of the transfused red blood cells, which poses significant risks including febrile reactions, hemolytic anemia, or more severe complications.

While crossmatching random units may seem viable due to the negative antibody screen, the history of anti-Jka presents a risk that should be mitigated by ensuring that the blood provided does not have the Jka antigen. Additionally, repeating the screen or requesting a new sample may not address the existing sensitization to the Jka antigen, as these actions do not change the compatibility requirements for the transfusion. Using enzyme-treated cells to repeat the screen also does not align with the best practice for managing known antibody history in transfusion settings. Thus, the safest and most effective practice is to utilize Jka